08:09 AM EDT, 10/29/2024 (MT Newswires) -- Harmony Biosciences Holdings ( HRMY ) reported Q3 adjusted earnings Tuesday of $1.03 per diluted share, up from $0.97 a year earlier.

Four analysts surveyed by Capital IQ expected $0.88.

Net product revenue for the quarter ended Sept. 30 was $186 million, up from $160.3 million a year earlier.

Analysts surveyed by Capital IQ expected $184.1 million.

The pharmaceutical company said it continues to expect fiscal 2024 net product revenue of $700 million to $720 million. Analysts surveyed by Capital IQ expect $710.1 million.

Shares of Harmony Biosciences ( HRMY ) were up nearly 3% in recent Tuesday premarket activity.

Price: 36.65, Change: +0.90, Percent Change: +2.52